GO
Loading...

Allergan Inc

More

  • Nov 17- Allergan Inc agreed to be bought by Actavis Plc for $66 billion, putting an end to a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. The offer values Allergan at $219 per share and is $6 billion more than the price Valeant had last offered to pay. Allergan shares rose 6.6 percent to $211, earning Ackman a...

  • Nov 17- Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson said on Monday that the company can't justify matching Actavis Plc's $219 per share bid for Allergan Inc..

  • Why Allergan never engaged Valeant   Monday, 17 Nov 2014 | 9:36 AM ET
    Why Allergan never engaged Valeant

    Allergan chairman & CEO David Pyott, explains why Allergan never engaged Valeant Pharmaceuticals and what's next for the newly combined companies.

  • Actavis CEO: Huge commitment to R&D   Monday, 17 Nov 2014 | 9:32 AM ET
    Actavis CEO: Huge commitment to R&D

    CNBC's Jim Cramer speaks to Brent Saunders, Actavis CEO, and David Pyott, Allergan chairman & CEO, about the growth and R&D budget of the combined companies going forward.

  • Actavis CEO: Allergan best run pharma company   Monday, 17 Nov 2014 | 9:30 AM ET
    Actavis CEO: Allergan best run pharma company

    CNBC's David Faber speaks to David Pyott, Allergan chairman & CEO, and Brent Saunders, Actavis CEO about their deal worth roughly $66 billion and what it means for shareholders.

  • Allergan agrees to Actavis deal for $66 billion Monday, 17 Nov 2014 | 9:20 AM ET

    Nov 17- Allergan Inc agreed to be bought by Actavis Plc for $66 billion, more than $12 billion above the current value of a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc. The offer values Allergan at $219 per share, compared with its Friday close of $198.65. Valeant's latest cash-and-stock offer is currently...

  • Stock futures decline as Japan slides into recession Monday, 17 Nov 2014 | 9:17 AM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks looked set to decline at the open on Monday, with global shares hit by the news that Japan had unexpectedly slipped into recession.

  • *Baker Hughes rallies on Halliburton deal; crude futures fall. *DreamWorks shares slide as Hasbro talks stall. Merger and acquisition news partly offset the declines as Halliburton said it would buy Baker Hughes and Allergan is close to a buyout by Actavis.

  • Early Movers: BHI, HAL, TSN, AGN, GM, MAR & more Monday, 17 Nov 2014 | 8:14 AM ET

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures slip as Japan dips into recession Monday, 17 Nov 2014 | 7:42 AM ET

    *Merger and acquisition news partly offset the declines as Halliburton said it would buy Baker Hughes and Allergan is close to a buyout deal by Actavis. *Baker Hughes rose 16.4 percent on news Halliburton would acquire it in a cash and stock transaction of about $34.6 billion. *Allergan added 4.5 percent as the Actavis buyout values the company as high as $65.5...

  • US stocks seen lower after Japan enters recession Monday, 17 Nov 2014 | 6:03 AM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks looked set to decline at the open on Monday, with global shares hit by the news that Japan had unexpectedly slipped into recession.

  • Nov 16- Allergan Inc is close to a buyout deal worth up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada's Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter. Actavis may pay Allergan between $215 and $220 per share, with the final price likely...

  • BUSINESS-NEWS-SCHEDULE AT 2200 GMT / 5 PM ET Sunday, 16 Nov 2014 | 4:46 PM ET

    WASHINGTON- President Barack Obama defends the transparency of his signature healthcare law after a White House adviser on the reform said the law passed, in part, because of the "stupidity" of American voters. ALLERGAN, ACTAVIS NEAR DEAL, ANNOUNCEMENT AS EARLY AS MONDAY. NEW YORK- Allergan nears a deal to merge with Actavis Plc, with an announcement coming as soon as...

  • Nov 16- Allergan Inc is near a deal to merge with Actavis Plc, with an agreement to be announced as soon as Monday, according to a person familiar with the matter. Actavis is likely to pay Allergan between $210 and $220 per share, according to the source. Actavis and Allergan declined to comment.

  • Actavis nears rescue bid for Allergan: Sources Sunday, 16 Nov 2014 | 2:52 PM ET

    Actavis is nearing a deal to acquire Allergan in a cash and stock deal worth more than $210 per Allergan share, sources tell CNBC.

  • Actavis would likely pay Allergan between $210 and $220 per share, according to the source.

  • NEW YORK, Nov 16- Allergan Inc is near making a friendly deal with Actavis Plc, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

  • Nov 12- Merger talks between Allergan Inc and white knight Actavis Plc are focused on narrowing a gap of about $3 billion between what has been offered and what is wanted, Bloomberg reported on Wednesday. Actavis is willing to pay around $200 per share, or $60 billion, while Allergan wants more than $210 per share, Bloomberg said. The amended laws now include a...

  • Midday movers: Dow Chemical, Google, Macy's & more Wednesday, 12 Nov 2014 | 12:48 PM ET
    New York Stock Exchange NYSE

    Some of Wednesday's midday movers:

  • Nov 12- Actavis Plc is in talks to buy Allergan Inc for at least $60 billion in a deal that could culminate this month, Bloomberg reported, citing sources familiar with the matter. The two companies are trying to narrow a gap of about $3 billion between what Actavis wants to pay and what Allergan is asking for, Bloomberg reported. Allergan, which is trying to fend off a...